New 6-In-One Vaccine Approved For Infants

Just when parents, and those concerned about vaccine safety issues, think it can’t get any worse regarding over-vaccination than it is, the U.S. CDC/FDA just approved a new six-active vaccine to be given to infants in three doses starting as early as 6 weeks of age. It’s called Vaxelis®, manufactured by Sanofi and distributed by Merck. “It’s approved as a three-dose series before children reach their fifth birthday.”

FiercePharma notes,

The manufacturing scale-up for Vaxelis comes as Sanofi and Merck both count on vaccines for future growth. For Sanofi, it also comes after a letdown for another recent vaccine launch, dengue shot Dengvaxia. Merck, for its part, is hoping its pipeline vaccine V114 can compete with Pfizer in the pneumococcal disease vaccine field, where Pfizer’s Prevnar 13 currently generates billions of dollars in annual sales. [1] [CJF emphasis]

According to the vaccine package insert [2], Vaxelis is

Manufactured by: Sanofi Pasteur Limited Toronto Ontario Canada for: MCM Vaccine Co. Swiftwater PA 18370 USA

Distributed by: Merck Sharp & Dohme Corp. A subsidiary of Merck & Co., Inc. Whitehouse Station NJ 08889 USA and Sanofi Pasteur Inc. Swiftwater PA 18370 USA

VAXELIS is a trademark of MCM Vaccine Company. The trademarks depicted herein are owned by their respective companies.

The Vaxelis packages insert state:

11 DESCRIPTION VAXELIS

(Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) is a sterile suspension for intramuscular injection. Each 0.5 mL dose is formulated to contain 15 Lf diphtheria toxoid, 5 Lf tetanus toxoid, acellular pertussis antigens [20 mcg detoxified pertussis toxin (PT), 20 mcg filamentous hemagglutinin (FHA), 3 mcg pertactin (PRN), 5 mcg fimbriae types 2 and 3 (FIM)], inactivated polioviruses [29 D-antigen units (DU) Type 1 (Mahoney), 7 DU Type 2 (MEF-1), 26 DU Type 3 (Saukett)], 3 mcg polyribosylribitol phosphate (PRP) of H. influenzae type b covalently bound to 50 mcg of the outer membrane protein complex (OMPC) of Neisseria meningitidis serogroup B, and 10 mcg hepatitis B surface antigen (HBsAg).

Each 0.5 mL dose contains 319 mcg aluminum from aluminum salts used as adjuvants.

Other ingredients per 0.5 mL dose include … read the package insert because my computer censor will not permit me to copy and paste the rest!!! [2] [CJF emphasis]